3results about How to "Good broad spectrum" patented technology

The invention provides a G-protein-targeted broad-spectrum high-neutralizing-activity rabies virus-resistant fully-humanized monoclonal antibody and application thereof, the fully-humanized monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GFAFNTYP, ISSYDGTDK and AKEFNPMVRQTIIIRRAGHDAFDI, and the light chain variable region has three complementary determining region amino acid sequences: GFAFNTYP, ISSYDGTDK and AKEFNPMVRQTIIIIRRAGHDAFDI. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QNIRTD, DAS and QQSNFWPIT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The present application relates to the technical field of biotechnology, and particularly relates to a CRISPR / SuCas12a2-based gene editing system and application thereof. The present application constructs a high-efficiency counter-selection recombination editing tool by exploring the counter-selection potential of CRISPR-SuCas12a2 and combining it with lambda recombinase. The method can complete high-efficiency recombination editing of genes through a double-plasmid and single-plasmid system carrying SuCas12a2 and lambda recombinase, and the efficiency is greatly improved compared with the current recombination editing method based on lambda recombinase. Compared with the previous dependence on the specific cleavage of target double-stranded DNA by CRISPR-Cas protein to promote the effect of recombination editing, the efficiency is also obviously improved, and the method has the advantages of more transformants and low probability of immune escape. The plasmid construction, recombination editing and plasmid elimination operations can be completed within one week. The above functions supplement a powerful tool for gene recombination editing.

The invention belongs to the field of medicine preparation, and particularly relates to a nano delivery carrier of IL-22BPmRNA (Interleukin-22BPmRNA). The invention aims to overcome the defect of less types of ionizable phospholipids for preparing LNP delivery mRNA. The technical scheme for solving the technical problem is to provide a nano delivery carrier of IL-22BPmRNA, which is prepared on the basis of a novel ionizable phospholipid molecule capable of being used for preparing a nucleic acid delivery carrier. The nano delivery carrier of the IL-22BPmRNA, disclosed by the invention, is good in stability. Experiments show that therapeutic RNA can be efficiently delivered to various human and mouse tumor cells, high-level protein expression is realized, and the polypeptide has unique advantages and good application prospects in the field.